Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Surrozen Inc. Warrant (SRZNW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/09/2025: SRZNW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -50% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/09/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.57 | 52 Weeks Range 0.01 - 0.09 | Updated Date 05/20/2025 |
52 Weeks Range 0.01 - 0.09 | Updated Date 05/20/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.7 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -971.62% |
Management Effectiveness
Return on Assets (TTM) -21.41% | Return on Equity (TTM) -456.32% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 5400593 |
Shares Outstanding - | Shares Floating 5400593 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Surrozen Inc. Warrant
Company Overview
History and Background
Surrozen, Inc. was a biotechnology company focused on discovering and developing targeted regenerative antibody therapeutics to repair tissues damaged by injury or disease. The warrants were connected to the initial SPAC merger. Surrozen ceased operations in 2023.
Core Business Areas
- Regenerative Medicine: Surrozen focused on developing antibody therapeutics designed to activate the Wnt signaling pathway to stimulate tissue regeneration. This included research and development efforts targeting various diseases.
Leadership and Structure
The company had a leadership team composed of executives in research and development, finance, and business operations. The organizational structure was typical of a clinical-stage biotech, with departments focused on specific aspects of drug development.
Top Products and Market Share
Key Offerings
- SZN-1326: A preclinical antibody therapeutic targeting liver diseases. There was no market share as it was in preclinical development. Competitors in the liver disease space include larger pharmaceutical companies with existing drugs or clinical trials. The market in this space is in the billions.
- SZN-043: A preclinical antibody therapeutic targeting intestinal diseases. There was no market share as it was in preclinical development. Competitors in the intestinal disease space include larger pharmaceutical companies with existing drugs or clinical trials. The market in this space is in the billions.
Market Dynamics
Industry Overview
The regenerative medicine industry is characterized by high-risk, high-reward ventures. It relies on scientific advancements, rigorous clinical trials, and substantial capital investment.
Positioning
Surrozen aimed to position itself as a leader in regenerative antibody therapeutics, specifically targeting Wnt signaling. They sought a competitive advantage through novel target engagement and tissue-specific regeneration.
Total Addressable Market (TAM)
The TAM for regenerative medicine is substantial, estimated to be in the tens of billions of dollars. Surrozen was positioned to capture a portion of this market by addressing unmet needs in liver and intestinal diseases.
Upturn SWOT Analysis
Strengths
- Novel Wnt signaling pathway approach
- Experienced scientific team
- Potential for targeted tissue regeneration
Weaknesses
- Early-stage clinical development
- High cash burn rate
- Reliance on clinical trial success
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new disease areas
- Positive clinical trial data
Threats
- Clinical trial failures
- Competition from established therapies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
Competitive Landscape
N/A
Growth Trajectory and Initiatives
Historical Growth: Prior to ceasing operations, the company's growth depended on clinical trial progress. The company had high growth objectives but failed to meet those objectives.
Future Projections: N/A, as the company ceased operations.
Recent Initiatives: Recent initiatives included preclinical studies and preparations for clinical trials prior to ceasing operations.
Summary
Surrozen Inc. Warrant was associated with a high-risk, clinical-stage biotechnology company focused on regenerative medicine. The company sought to revolutionize treatment for liver and intestinal diseases through innovative antibody therapeutics targeting the Wnt signaling pathway. However, due to challenging market conditions and clinical trial uncertainty, the company ultimately ceased operations, resulting in significant losses for shareholders. Investors should have been aware of the risks associated with clinical-stage biotechnology companies before investing. The company's failure highlights the inherent dangers of investing in preclinical drugs.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website (Historical Data)
- Third-Party Financial Analysis Sites
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Due to the company having ceased operations, much of the data is now historical.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Surrozen Inc. Warrant
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2021-08-12 | CEO, President & Director Mr. Craig C. Parker M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 40 | Website https://www.surrozen.com |
Full time employees 40 | Website https://www.surrozen.com | ||
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs' endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.